-
G1 Therapeutics NASDAQ:GTHX G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
Location: 700 Park Offices Drive, Suite 200, North Carolina, 27709, US | Website: www.g1therapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
364.5M
Cash
60.73M
Avg Qtr Burn
-9.385M
Short % of Float
8.71%
Insider Ownership
10.92%
Institutional Own.
54.62%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details Cancer, Solid tumor/s, Small cell lung cancer | Approved Quarterly sales | |
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Breast cancer, Cancer, Triple-negative breast cancer | Phase 3 Update | |
Trilaciclib (Cosela) (CDK4/6 inhibitor) + avelumab Details Solid tumor/s, Cancer, Bladder cancer | Phase 2 Update | |
Trilaciclib (Cosela) + Trodelvy® (sacituzumab govitecan-hziy) (ADC) Details Solid tumor/s, Cancer, Metastatic breast cancer, Triple-negative breast cancer , Breast cancer | Phase 2 Update | |
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Solid tumor/s | Phase 2 Update | |
Rintodestrant + palbociclib Details Breast cancer | Failed Discontinued | |
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s | Failed Discontinued | |
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Colorectal cancer , Cancer | Failed Discontinued |